Bloomberg News

Boehringer Ingelheim Says NICE Issues Pradaxa Recommendation

November 02, 2011

Nov. 2 (Bloomberg) -- Boehringer Ingelheim said the National Institute for Health and Clinical Excellence in the United Kingdom has issued a Final Appraisal Determination recommending its Pradaxa oral anticoagulant as a treatment option, the company said in an e-mailed statement today. The licensed indication is for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation with one or more risk factors and the institute’s recommendation is without any restrictions within the indication.

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus